Transforming Growth Factor β Neutralization Ameliorates Pre-Existing Hepatic Fibrosis and Reduces Cholangiocarcinoma in Thioacetamide-Treated Rats

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Ling, Hong ^a   Roux, Eric ^a   Hempel, Donna ^a   Tao, Jingzang ^a   Smith, Mandy ^a   Lonning, Scott ^a   Zuk, Anna ^a   Arbeeny, Cynthia ^a   Ledbetter, Steve ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; COLLAGEN; HYDROXYPROLINE; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1D11; PLASMINOGEN ACTIVATOR INHIBITOR 1; THIOACETAMIDE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CARCINOMA; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE EXPRESSION; HISTOPATHOLOGY; LIVER FIBROSIS; LIVER HISTOLOGY; NONHUMAN; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CHOLANGIOCARCINOMA; HUMAN; IMMUNOLOGY; LIVER; LIVER CIRRHOSIS; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TOXICITY; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM;

ANIMALIA; MURINAE; RATTUS;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHOLANGIOCARCINOMA; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MICE; MOLECULAR TARGETED THERAPY; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; SIGNAL TRANSDUCTION; THIOACETAMIDE; TRANSFORMING GROWTH FACTOR BETA;

EID: 84872510074     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054499     Document Type: Article

References (35)

1. Friedman SL, (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134: 1655-1669.
2. Jiao JJ, Friedman SL, Aloman C, (2009) Hepatic fibrosis. Curr Opin Gastroenterol 25: 223-229.
3. Bataller R, Brenner DA, (2005) Liver fibrosis. J Clin Invest 115: 209-218.
4. Friedman SL, (2007) Reversibility of Hepatic Fibrosis and Cirrhosis- Is it all Hype? Nat Clin Pract Gastroenterol Hepatol 4: 236-237.
5. Tangkijvanich P, Yee HF (2002) Cirrhosis- can we reverse hepatic fibrosis? Eur J Surg Suppl 587: 100-12.
6. Povero D, Busletta C, Novo E, di Bonzo LV, Cannito S, et al. (2010) Liver fibrosis: a dynamic and potentially reversible process. Histol Histopathol 25: 1075-91.
7. Gressner AM, Weiskirchen R, (2006) Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets. J Cellular and Molecular Medicine 10: 76-99.
8. Gressner OA, Rizk MS, Kovalenko E, Weiskirchen R, Gressner AM, (2008) Changing the pathogenetic roadmap of liver fibrosis? Where did it start; where will it go? J Gastroenterol Hepatol 23: 1024-35.
9. Liu X, Hu H, Yin JQ, (2006) Therapeutic strategies against TGF-β signaling pathway in hepatic fibrosis. Liver Int 26: 8-22.
10. Bergheim I, Guo L, Davis MA, Duveau I, Arteel GE, (2006) Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis. J Pharmacol Exp Ther 316: 592-600.
11. Arteel GE, (2008) New role of plasminogen activator inhibitor-1 in alcohol-induced liver injury. J Gastroenterol Hepatol 23: S54-9.
12. DM Bissell, (2001) Chronic liver injury, TGF-beta, and cancer. Exp Mol Med 33: 179-90.
13. Kaminska B, Wesolowska A, Danilkiewicz M, (2005) TGF beta signaling and its role in tumour pathogenesis. Acta Biochimica Polonica 52: 329-337.
14. Derynck R, Akhurst RJ, Balmain A, (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29: 117-29.
15. Matsuzaki K, Okazaki K, (2006) Transforming growth factor-β during carcinogenesis: the shift from epithelial to mesenchymal signaling. J Gastroenterology 41: 295-303.
16. Marquez-Aguirre AM, Sandoval-Rodriguez A, Gonzalez-Cuevas J, Bueno-Topete M, (2009) Adenoviral delivery of dominant-negative transforming growth factor β type II receptor up-regulates transcriptional repressor SKI-like oncogene, decreases matrix metalloproteinase 2 in hepatic stellate cell and prevents liver fibrosis in rats. The Journal of Gene Medicine 11: 207-2199.
17. Yata Y, Gotwals P, Koteliansky V, Rockey DC, (2002) Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-β soluble receptor: implications for antifibrotic therapy. Hepatology 35: 1022-30.
18. George J, Roulot D, Koteliansky VE, Bissell DM, (1999) In vivo inhibition of rat stellate cell activation by soluble transforming growth factor β type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci USA 96: 12719-24.
19. Xu W, Wang LW, Shi JZ, Gong ZJ, (2009) Effects of RNA interference targeting transforming growth factor-beta 1 on immune hepatic fibrosis induced by concanavalin A in mice. Hepatobiliary Pancreat Dis Int 8: 300-8.
20. Al-Bader A, Mathew TC, Abul H, Al-Sayer H, Singal PK, et al. (2000) Cholangiocarcinoma and liver cirrhosis in relation to changes due to thioacetamide. Mol Cell Biochem 208: 1-10.
21. Yeh CN, Maitra A, Lee KF, Jan YY, Chen MF, (2004) Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma. Carcinogenesis 25: 631-6.
22. Pilette C, Rousselet MC, Bedossa P, Chappard D, Oberti F, et al. (1998) Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J Hepatol 28: 439-46.
23. Stroescu C, Herlea V, Dragnea A, Popescu I, (2006) The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas. J Gastrointest Liver Dis 15: 9-14.
24. Guerra RR, Trotta MR, Aloia TPA, Dagli MLZ, Hernandez-Blazquez FJ, (2010) A novel chronic cirrhosis TAA-induced model in rats. Braz J Vet Pathol 3: 9-16.
25. Derynck R, Zhang YE, (2003) Smad-dependent and Smad-independent pathways in TGF- family signaling. Nature 425: 577-584.
26. Tsukamoto H, Matsuoka M, French SW, (1990) Experimental models of hepatic fibrosis: Semin Liver Dis. 10: 56-65.
27. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, et al. (2010) Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 52: 886-93.
28. Pérez Roldán F, Vives Domínguez L, González Carro P, Villafáñez García MC, Fernández Acenero MJ, et al. (2010) Reversibility of hepatitis B virus-induced liver cirrhosis after prolonged antiviral therapy. Gastroenterol Hepatol 33: 498-503.
29. Martínez-Rizo A, Bueno-Topete M, González-Cuevas J, Armendáriz-Borunda J, (2010) Plasmin plays a key role in the regulation of profibrogenic molecules in hepatic stellate cells. Liver Int 30: 298-310.
30. Hu PF, Chen H, Zhong W, Lin Y, Zhang X, et al. (2009) Adenovirus-mediated transfer of siRNA against PAI-1 mRNA ameliorates hepatic fibrosis in rats. J Hepatology 51: 102-113.
31. Wang H, Vohra BP, Zhang Y, Heuckeroth RO, (2005) Transcriptional profiling after bile duct ligation identifies PAI-1 as a contributor to cholestatic injury in mice. Hepatology 42: 1099-108.
32. Wang H, Zhang Y, Heuckerotha RO, (2007) PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA. FEBS Letters 581: 3098-3104.
33. Bhowmick NA, Neilson EG, Moses HL, (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432: 332-337.
34. Whittaker S, Marais R, Zhu AX, (2010) The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 9: 4989-5005.
35. Farazi PA, Zeisberg M, Glickman J, Zhang Y, Kalluri R, et al. (2006) Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res 66: 6622-6627.